New York Life Investment Management LLC Has $17.15 Million Stock Holdings in Danaher Corporation $DHR

New York Life Investment Management LLC raised its stake in Danaher Corporation (NYSE:DHR) by 1.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 86,821 shares of the conglomerate’s stock after buying an additional 1,061 shares during the quarter. New York Life Investment Management LLC’s holdings in Danaher were worth $17,151,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Invesco Ltd. increased its stake in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after purchasing an additional 163,332 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $221.20 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The firm has a fifty day moving average price of $202.97 and a two-hundred day moving average price of $198.77. The company has a market cap of $156.24 billion, a PE ratio of 45.61, a price-to-earnings-growth ratio of 3.41 and a beta of 0.77.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the firm earned $1.71 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Robert W. Baird set a $247.00 target price on shares of Danaher in a research note on Wednesday, October 22nd. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.